The terms racemic mixtures, single isomers, prodrugs, active metabolites, extended-release mechanisms were once remembered as the topics of early pharmacy school curriculum. Now they are often the source of confusion for practitioners and, sometimes, big money for manufacturers. Since 2011, nearly ten percent of the top 100 medications by sales were “new and improved” versions of previously released products with 4–5% being revised psychotropics.1 Since these “new” products are released as brand name agents under patent protection, they are often priced much higher than their predecessors. Clinical evidence is limited to approval trials – a handful of placebo-controlled